Home › Companies › SYNDAX PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and SYNDAX PHARMACEUTICALS INC.’s Form 8-K, filed 2024-05-15 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore SYNDAX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are SYNDAX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-15 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Martin H. Huber, M.D. | 61,876,711 | -- | -- | 736,625 | 3,032,770 | Majority: yes |
| Elect Director: Jennifer Jarrett | 39,491,936 | -- | -- | 23,121,400 | 3,032,770 | Majority: yes |
| Elect Director: William Meury | 54,416,889 | -- | -- | 8,196,447 | 3,032,770 | Majority: yes |
| Proposal 2: Advisory vote on executive compensation: | 46,228,421 | 16,304,796 | 80,119 | -- | 3,032,770 | Majority: yes |
| Proposal 3: Ratification of selection of independent registered public accounting firm: | 65,371,337 | 253,270 | 21,499 | -- | -- | Majority: yes |
Source: SYNDAX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-05-15 — read the filing on EDGAR.
Each item below shows how the 215 asset managers that disclosed a SYNDAX PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Advisory vote on executive compensation:”): 46,228,421 for, 16,304,796 against, per its Form 8-K filed 2024-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,979,686 outstanding shares: 54.4% for, 19% against (74% of the company cast a for/against vote).
The 212 asset managers below cast 70% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,854,878 | 4,249,352 | 0 | 0 | For |
| State Street | 7,902,372 | 0 | 0 | 0 | For |
| Wellington | 0 | 7,027,115 | 0 | 0 | Against |
| BlackRock | 6,622,524 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 5,660,000 | 0 | Abstain |
| T. Rowe Price | 3,773,011 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 3,225,997 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 2,048,017 | 0 | 0 | Against |
| BVF INC/IL | 1,875,000 | 0 | 0 | 0 | For |
| Fidelity | 1,805,224 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,781,607 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 0 | 1,752,627 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 0 | 1,749,000 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 1,394,514 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,268,658 | 0 | 0 | Against |
| Aisling Capital Management LP | 1,025,000 | 0 | 0 | 0 | For |
| JPMorgan | 1,014,675 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 999,934 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 930,287 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 900,000 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 0 | 887,094 | 0 | 0 | Against |
| Foresite Capital Management IV, LLC | 875,000 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Northern Trust | 722,522 | 44 | 0 | 0 | For |
| Federated Hermes | 709,328 | 0 | 0 | 0 | For |
Showing the 25 largest of 212 asset managers. See all 212 in the interactive database.
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jennifer Jarrett”): 39,491,936 for, 23,121,400 withheld, per its Form 8-K filed 2024-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,979,686 outstanding shares: 46.5% for, 27% withheld (74% of the company cast a for/withheld vote).
The 68 asset managers below cast 100% of the shares they voted on this item FOR (16,535,343 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 3,561,811 | 0 | 0 | 0 | For |
| State Street | 3,133 | 0 | 3,196,274 | 0 | Abstain |
| Fidelity | 1,771,614 | 0 | 0 | 0 | For |
| T. Rowe Price | 14,587 | 0 | 1,353,833 | 0 | Abstain |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 634,277 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 470,690 | 0 | Abstain |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 409,750 | 0 | Abstain |
| TIAA | 0 | 0 | 390,922 | 0 | Abstain |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 219,075 | 0 | Abstain |
| Equitable | 121,199 | 0 | 76,160 | 0 | For |
| John Hancock | 96,114 | 0 | 93,926 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 180,000 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 138,102 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 0 | 0 | 137,480 | 0 | Abstain |
| Brighthouse | 33,027 | 0 | 100,438 | 0 | Abstain |
| Dimensional | 0 | 0 | 103,530 | 0 | Abstain |
| Prudential/PGIM | 56,452 | 0 | 39,202 | 0 | For |
| Allspring | 0 | 0 | 94,139 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 94,025 | 0 | Abstain |
| Victory Capital | 1,653 | 0 | 77,970 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 75,145 | 0 | Abstain |
Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Martin H. Huber, M.D.”): 61,876,711 for, 736,625 withheld, per its Form 8-K filed 2024-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,979,686 outstanding shares: 73% for, 0.9% withheld (74% of the company cast a for/withheld vote).
The 68 asset managers below cast 100% of the shares they voted on this item FOR (24,585,931 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 3,561,811 | 0 | 0 | 0 | For |
| State Street | 3,199,027 | 0 | 380 | 0 | For |
| Fidelity | 1,740,912 | 0 | 30,702 | 0 | For |
| T. Rowe Price | 1,368,420 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 634,277 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 470,690 | 0 | 0 | 0 | For |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 409,750 | 0 | 0 | 0 | For |
| TIAA | 390,922 | 0 | 0 | 0 | For |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 219,075 | 0 | 0 | 0 | For |
| Equitable | 121,199 | 0 | 76,160 | 0 | For |
| John Hancock | 190,040 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 138,102 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 137,480 | 0 | 0 | 0 | For |
| Brighthouse | 115,725 | 0 | 17,740 | 0 | For |
| Dimensional | 0 | 0 | 103,530 | 0 | Abstain |
| Prudential/PGIM | 95,654 | 0 | 0 | 0 | For |
| Allspring | 94,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 94,025 | 0 | 0 | 0 | For |
| Victory Capital | 79,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,145 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.
Combines 3 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William Meury”): 54,416,889 for, 8,196,447 withheld, per its Form 8-K filed 2024-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,979,686 outstanding shares: 64% for, 10% withheld (74% of the company cast a for/withheld vote).
The 68 asset managers below cast 100% of the shares they voted on this item FOR (20,578,485 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 3,561,811 | 0 | Abstain |
| State Street | 3,199,027 | 0 | 380 | 0 | For |
| Fidelity | 1,691,352 | 0 | 80,262 | 0 | For |
| T. Rowe Price | 1,368,420 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 634,277 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 470,690 | 0 | 0 | 0 | For |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 409,750 | 0 | 0 | 0 | For |
| TIAA | 390,922 | 0 | 0 | 0 | For |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 219,075 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 197,359 | 0 | Abstain |
| John Hancock | 190,040 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 138,102 | 0 | Abstain |
| Exchange Place Advisors Trust | 137,480 | 0 | 0 | 0 | For |
| Brighthouse | 115,725 | 0 | 17,740 | 0 | For |
| Dimensional | 0 | 0 | 103,530 | 0 | Abstain |
| Prudential/PGIM | 95,654 | 0 | 0 | 0 | For |
| Allspring | 94,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 94,025 | 0 | 0 | 0 | For |
| Victory Capital | 79,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,145 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Ratification of selection of independent registered public accounting firm:”): 65,371,337 for, 253,270 against, per its Form 8-K filed 2024-05-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,979,686 outstanding shares: 77% for, 0.3% against (77% of the company cast a for/against vote).
The 68 asset managers below cast 99.9% of the shares they voted on this item FOR (24,803,846 for, 715 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 3,561,811 | 0 | 0 | 0 | For |
| State Street | 3,198,901 | 506 | 0 | 0 | For |
| Fidelity | 1,771,614 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,368,420 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 634,277 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 470,690 | 0 | 0 | 0 | For |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 409,750 | 0 | 0 | 0 | For |
| TIAA | 390,922 | 0 | 0 | 0 | For |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 219,075 | 0 | 0 | 0 | For |
| Equitable | 197,359 | 0 | 0 | 0 | For |
| John Hancock | 190,040 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 138,102 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 137,480 | 0 | 0 | 0 | For |
| Brighthouse | 115,725 | 0 | 17,740 | 0 | For |
| Dimensional | 103,530 | 0 | 0 | 0 | For |
| Prudential/PGIM | 95,654 | 0 | 0 | 0 | For |
| Allspring | 94,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 94,025 | 0 | 0 | 0 | For |
| Victory Capital | 79,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,145 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.
Ranked by the number of SYNDAX PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 84,979,686 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.71% |
| 2 | State Street | 9.30% |
| 3 | Wellington | 8.27% |
| 4 | BlackRock | 7.79% |
| 5 | Kynam Capital Management, LP | 6.66% |
| 6 | T. Rowe Price | 4.44% |
| 7 | Eversept Partners, LP | 3.80% |
| 8 | MARSHALL WACE, LLP | 2.41% |
| 9 | BVF INC/IL | 2.21% |
| 10 | Fidelity | 2.12% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 10.15% | 13F |
| Entities affiliated with Wellington Group, LLP. | 8.93% | DEF14A |
| Wellington Management | 8.75% | 13F |
| Entities affiliated with BlackRock, Inc. | 8.26% | DEF14A |
| Entities affiliated with Kynam Capital Management, LP | 6.66% | DEF14A |
| Goldman Sachs | 6.46% | 13F |
| Vanguard Group | 6.05% | 13F |
| State Street | 5.67% | 13F |
| S | 4.65% | 13G |
| Point72 | 2.43% | 13F |
Percentages above are of 84,979,686 shares outstanding, as reported by SYNDAX PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SYNDAX PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At SYNDAX PHARMACEUTICALS INC.'s shareholder meeting held 2024-05-15, in the 2023-2024 proxy season, 215 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,261 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SYNDAX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-15.
SYNDAX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.